Search research articles
Contact Us
Filters
Showing results (171-180 of 195) with videos related to
Page
of 20
Sort By:
Molecular Cancer Therapeutics
|
June 5, 2021
Venetoclax-based Rational Combinations are Effective in Models of <i>MYCN</i>-amplified Neuroblastoma
Krista M Dalton, Kateryna Krytska, Timothy L Lochmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 24, 2018
The Ewing Family of Tumors Relies on BCL-2 and BCL-X<sub>L</sub> to Escape PARP Inhibitor Toxicity
Daniel A R Heisey, Timothy L Lochmann, Konstantinos V Floros, et al.
Chemical Research in Toxicology
|
October 13, 2025
Industry Perspective on Nonclinical Approaches for Hepatotoxicity Risk Assessment: Insights from Two Longitudinal Surveys Conducted in 2023 and 2017
Melanie Z Sakatis, Leah M Norona, Jamie E Karmel, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 25, 2021
Catastrophic ATP loss underlies a metabolic combination therapy tailored for <i>MYCN</i>-amplified neuroblastoma
Krista M Dalton, Timothy L Lochmann, Konstantinos V Floros, et al.
Cancer Research
|
January 23, 2021
<i>MYCN</i>-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis
Konstantinos V Floros, JinYang Cai, Sheeba Jacob, et al.
PNAS Nexus
|
January 30, 2023
Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models
Sheeba Jacob, Tia H Turner, Jinyang Cai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2017
Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression
Timothy L Lochmann, Konstantinos V Floros, Mitra Naseri, et al.
Biorxiv : the Preprint Server for Biology
|
November 24, 2025
E2 displacement of CIP2A from TOPBP1 activates the DNA damage response during papillomavirus life cycles
Apurva T Prabhakar, Claire D James, Allison Q Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 9, 2018
Increased Synthesis of MCL-1 Protein Underlies Initial Survival of <i>EGFR</i>-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target
Kyung-A Song, Yasuyuki Hosono, Crystal Turner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2012
Activation of PI3K signaling in Merkel cell carcinoma
Valentina Nardi, Youngchul Song, Juan A Santamaria-Barria, et al.
Page
of 20
Search research articles
Search
Showing results (171-180 of 195) with videos related to
Sort By:
Page
of 20
Molecular Cancer Therapeutics
|
June 5, 2021
Venetoclax-based Rational Combinations are Effective in Models of <i>MYCN</i>-amplified Neuroblastoma
Krista M Dalton, Kateryna Krytska, Timothy L Lochmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 24, 2018
The Ewing Family of Tumors Relies on BCL-2 and BCL-X<sub>L</sub> to Escape PARP Inhibitor Toxicity
Daniel A R Heisey, Timothy L Lochmann, Konstantinos V Floros, et al.
Chemical Research in Toxicology
|
October 13, 2025
Industry Perspective on Nonclinical Approaches for Hepatotoxicity Risk Assessment: Insights from Two Longitudinal Surveys Conducted in 2023 and 2017
Melanie Z Sakatis, Leah M Norona, Jamie E Karmel, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 25, 2021
Catastrophic ATP loss underlies a metabolic combination therapy tailored for <i>MYCN</i>-amplified neuroblastoma
Krista M Dalton, Timothy L Lochmann, Konstantinos V Floros, et al.
Cancer Research
|
January 23, 2021
<i>MYCN</i>-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis
Konstantinos V Floros, JinYang Cai, Sheeba Jacob, et al.
PNAS Nexus
|
January 30, 2023
Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models
Sheeba Jacob, Tia H Turner, Jinyang Cai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2017
Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression
Timothy L Lochmann, Konstantinos V Floros, Mitra Naseri, et al.
Biorxiv : the Preprint Server for Biology
|
November 24, 2025
E2 displacement of CIP2A from TOPBP1 activates the DNA damage response during papillomavirus life cycles
Apurva T Prabhakar, Claire D James, Allison Q Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 9, 2018
Increased Synthesis of MCL-1 Protein Underlies Initial Survival of <i>EGFR</i>-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target
Kyung-A Song, Yasuyuki Hosono, Crystal Turner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2012
Activation of PI3K signaling in Merkel cell carcinoma
Valentina Nardi, Youngchul Song, Juan A Santamaria-Barria, et al.
Page
of 20